Skip to main content

Table 2 Efficacy variables in the studied groups

From: Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?

 

BTX-A

Placebo

P value

Mean

SD

Mean

SD

Paroxysm frequency /day

Baseline

36.7

3.13

39.20

3.05

0.087

Endpoint

4.0

7.12

36.10

13.45

0.0001

Number of weekly acute medications

Baseline

32

2.11

30.9

1.79

0.225

Endpoint

4.7

2.31

30.3

1.77

0.0001

QoL scale

Baseline

3.10

0.88

3.10

1.10

1.0

Endpoint

9.0

1.49

3.40

0.97

0.0001